ERBB2 and breast carcinoma: Rodrigues et al.[12] in their retrospective multicenter cohort of 276 cases of HER2 + pT1abN0 breast cancer reported a significantly higher DFS in patients who received adjuvant trastuzumab-based chem otherapy.